efore the advent of endomyocardial biopsy in the 1960s, myocarditis was known as an uncommon cause of acute and fatal heart failure. Biopsy and later cardiac magnetic resonance imaging (MRI) revealed that myocarditis was both more common and less lethal than originally described. With greater use of imaging and biopsy, the clinical spectrum of myocarditis broadened to include milder presentations such as pericarditis with elevated troponin values, nonsustained ventricular arrhythmias, and occasionally heart block.
B
efore the advent of endomyocardial biopsy in the 1960s, myocarditis was known as an uncommon cause of acute and fatal heart failure. Biopsy and later cardiac magnetic resonance imaging (MRI) revealed that myocarditis was both more common and less lethal than originally described. With greater use of imaging and biopsy, the clinical spectrum of myocarditis broadened to include milder presentations such as pericarditis with elevated troponin values, nonsustained ventricular arrhythmias, and occasionally heart block. 1 Patients who present with severe heart failure of <2-week symptom duration requiring parenteral inotropic or mechanical circulatory support are defined as having fulminant myocarditis. These relatively uncommon patients have a high risk in the near term of heart transplantation and death. 2 The cause of fulminant myocarditis historically was often an enteroviral (eg, Coxsackie virus) infection. As enterovirus prevalence has waned, new causes of fulminant myocarditis, including H1N1 influenza, 3 and drug-related eosinophilic myocarditis 4, 5 have emerged. Fulminant myocarditis, as described by Lieberman et al 6 in 1991, was a clinical and a pathological entity. Clinically, all subjects had a distinct viral prodrome and severe hemodynamic compromise. Pathologically, all cases had an active inflammatory infiltrate of lymphocytes and macrophages with myocyte necrosis. No subjects with fulminant myocarditis in the original description had giant cell myocarditis. Lymphocytic myocarditis that presents with a distinct viral prodrome and severe hemodynamic compromise was later shown to paradoxically have a good long-term prognosis if patients survived the acute episode. Specific forms of myocarditis such as giant cell and necrotizing eosinophilic myocarditis that have a poor prognosis were not included in this or more recent reports with good long-term outcome. 7 Ammirati et al 8 report in this issue a contemporary series of 187 patients with acute myocarditis. They observed that subjects with a fulminant presentation had a greater rate of in-hospital death or transplantation (25.5% versus 0%) and lower long-term survival (64.5% versus 100%) than patients with nonfulminant myocarditis. A subgroup analysis of fulminant and nonfulminant patients >15 years of age with <2 weeks of symptoms and biopsy-confirmed viral myocarditis had similar findings. Their observation of worse transplantation-free survival in fulminant myocarditis cohorts appears to contradict the earlier case series.
Differences in patient cohorts and study designs may explain the divergent outcomes (Table) In the fulminant group in the Ammirati et al series, 6 patients had giant cell myocarditis and 5 patients had eosinophilic myocarditis. All 11 of these patients died or required heart transplantation or a ventricular assist device. Patients with these specific forms of myocarditis were excluded from the McCarthy et al myocarditis cohort. Seventeen patients in the fulminant group in the Ammirati et al series were diagnosed by clinical presentation without biopsy. Some of these subjects may have had a more aggressive histological form of myocarditis. In addition to differences in the clinical spectrum of nonfulminant myocarditis, advances in the management of systolic heart failure may explain the better outcomes in the present study.
The high mortality in the fulminant myocarditis group in the Ammirati et al series may also reflect the changes in patient cohorts that have resulted from greater use of cardiac MRI over the last 30 years. Patients diagnosed by MRI while stable hemodynamically can progress over days or weeks to require inotropic support and meet criteria for fulminant disease. Having failed a trial of standard treatment, they would be selected to be at high risk for death or transplantation. The clinical implication is that a fraction of patients diagnosed with myocarditis by MRI will have a progressive course despite guideline-directed medical care, and these patients should be referred for biopsy. A 2007 American Heart Association/American College of Cardiology Foundation/European Society of Cardiology scientific statement assigned a Class I (is recommended), Level of Evidence B (moderate-quality evidence) recommendation for biopsy in the clinical scenario of acute progressive heart failure and suspected fulminant myocarditis, leading to a greater use of early biopsy. 9 Compared with older case series, patients in the new series may be less likely to die or to receive a transplantation without biopsy. More acute mortality from fulminant myocarditis would be reported in autopsy literature because of less frequent use of biopsy in the past. With greater use of biopsy, the deaths from fulminant myocarditis are increasingly captured in clinical heart failure series. The 2016 American Heart Association scientific statement on the management of specific cardiomyopathies notes that MRI may be helpful but biopsy is essential to identify specific high-risk histological features that add incremental prognostic and therapeutic information in this scenario. 10 The findings by Ammirati et al do not directly contradict earlier studies; rather, they add important observations in an era when heart biopsy and cardiac MRI are used more widely to diagnose myocarditis. Changes in the causes, clinical spectrum, and histological definition of myocarditis in the last few decades have affected the long-term prognosis and management of myocarditis in referral centers with advanced imaging and molecular diagnostic tools to study biopsy tissue. Patients with myocarditis with preserved or mildly reduced left ventricular function have a low rate of chronic dilated cardiomyopathy. The present study also serves to highlight the many unresolved questions about the timing of mechanical circulatory support and the use of immunosuppression in fulminant myocarditis. The transition from acute myocarditis to chronic dilated cardiomyopathy in human disease remains poorly understood. 11 In general, studies of adults with myocarditis published from eastern Asia 12 describe a higher rate of inotrope and mechanical circulatory support use than series from Western Europe and North America. It is not clear whether these clinical differences are related to subject selection or to differences in the biology of the disease across different populations. Outcomes in men and women differ for myocarditis in general, but more data are needed on sex differences in the fulminant subgroup. 13 Last, a better understanding of the interactions between hemodynamic unloading and immunological damage may help clinicians improve the remarkable degree of left ventricular recovery seen in studies of mechanical circulatory support for fulminant myocarditis. 
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